Edmond DE Rothschild Holding S.A. Purchases New Position in IQVIA Holdings Inc. $IQV

Edmond DE Rothschild Holding S.A. purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 411,578 shares of the medical research company’s stock, valued at approximately $79,525,000. IQVIA comprises about 1.0% of Edmond DE Rothschild Holding S.A.’s investment portfolio, making the stock its 22nd largest position. Edmond DE Rothschild Holding S.A. owned 0.25% of IQVIA as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Brighton Jones LLC raised its stake in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA during the second quarter worth about $514,000. First Trust Advisors LP lifted its holdings in shares of IQVIA by 14.8% in the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of IQVIA by 5.4% in the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after purchasing an additional 1,155 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In related news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The shares were sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. Company insiders own 1.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on IQV. Stifel Nicolaus raised their price target on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. TD Cowen increased their price objective on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Finally, Robert W. Baird increased their price target on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Stock Up 4.0%

IQV opened at $249.62 on Thursday. The business has a 50 day moving average price of $210.23 and a two-hundred day moving average price of $186.82. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $41.09 billion, a PE ratio of 30.97, a P/E/G ratio of 2.04 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $251.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.